Aurinia Pharmaceuticals Inc. (AUPH)
AUPHNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$16.62
+0.1600 (+0.97%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $2.23bn
- P/E
- 16.3
- EPS, last 4 quarters
- $1.02
- Dividend yield
- –
- Day range
- –
- 52-week range
- $13.52 to $19.25
- Average volume
- 841.0k
- Previous close
- $16.46
Analysts
3 coveringBuy2 buy, 1 hold, 0 sell
Targets a year out average $19.00, +14.3% from here
Earnings
next estimate $0.2400Next report
Dec 2025
+23.8%
Mar 2026
+38.9%
Jun 2026
+55.6%
Sep 2026
+15.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $77.11m | $77.70m | $83.22m | $83.70m |
| Gross profit | $68.31m | $71.20m | $76.67m | $75.39m |
| Operating income | $33.24m | $41.42m | $46.34m | $35.36m |
| Net income | $210.79m | $34.35m | $37.41m | $31.70m |
Last four quarters: revenue $321.74m, margin 97.7%, free cash flow –
News
8 latest- Aurinia Pharmaceuticals Inc. Q3 Sales Increase RTTNews · Oct 30, 2026
- Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings EstimatesZacks · Oct 30, 2026
- Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to DeclineZacks · Oct 28, 2026
- Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to DeclineZacks · Oct 27, 2026
- Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-TermZacks · Oct 26, 2026
- Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-TermZacks · Oct 23, 2026
- Notable Thursday Option Activity: DHT, AUPH, ONTBNK Invest · Sep 24, 2026
- Aurinia Settles Voclosporin Patent Litigation With Teva, Stock RisesZacks · Aug 20, 2026
The company
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021 , the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- auriniapharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.